RecruitingNot ApplicableNCT06220721

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia


Sponsor

Medical College of Wisconsin

Enrollment

618 participants

Start Date

Oct 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria5

  • Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
  • Postpartum day 0-4
  • Age ≥ 18 years
  • Able to communicate in English or in Spanish
  • Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records.

Exclusion Criteria9

  • Pre-gestational hypertension
  • Type 1 or type 2 diabetes mellitus
  • Admitted to intensive care unit at the time of screening
  • Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization
  • Getting discharged on the day of screening
  • Known allergy or contraindication to nifedipine ER
  • Inability or unwillingness to provide informed consent
  • Already taking long-acting antihypertensive medication for standard care
  • Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus

Interventions

DRUGNifedipine ER

Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.


Locations(2)

Northwestern University

Chicago, Illinois, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06220721


Related Trials